Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie